Vitamab

Vitamab is a Manchester-based biotechnology company developing conjugation technology to strengthen the antibody-drug conjugate manufacturing supply chain.

Its proprietary system uses accessible, lower-toxicity materials in place of scarce or hazardous reagents, aiming to reduce production costs and environmental impact while helping manufacturers meet emerging European regulatory requirements.

Vitamab works with bioconjugation scientists, CDMOs and regulatory teams to support ADC developers in maintaining reliable material sourcing and meeting clinical development timelines.